These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 27454287

  • 1. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
    Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.
    J Clin Invest; 2016 Aug 01; 126(8):2903-18. PubMed ID: 27454287
    [Abstract] [Full Text] [Related]

  • 2. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.
    Proc Natl Acad Sci U S A; 2008 Nov 04; 105(44):17079-84. PubMed ID: 18971340
    [Abstract] [Full Text] [Related]

  • 3. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    van de Ven M, van der Burg E, van der Gulden H, Klarenbeek S, Bouwman P, Jonkers J.
    J Pathol; 2017 Mar 04; 241(4):511-521. PubMed ID: 27943283
    [Abstract] [Full Text] [Related]

  • 4. RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
    Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N.
    J Clin Invest; 2016 Aug 01; 126(8):3145-57. PubMed ID: 27454289
    [Abstract] [Full Text] [Related]

  • 5. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
    Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.
    Cancer Discov; 2013 Jan 01; 3(1):68-81. PubMed ID: 23103855
    [Abstract] [Full Text] [Related]

  • 6. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
    Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J.
    Cancer Discov; 2013 Oct 01; 3(10):1142-55. PubMed ID: 23867111
    [Abstract] [Full Text] [Related]

  • 7. EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.
    Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler R, Linn S, Jonkers J.
    Clin Cancer Res; 2019 Jul 15; 25(14):4351-4362. PubMed ID: 31036541
    [Abstract] [Full Text] [Related]

  • 8. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW, Tewari KS.
    Curr Treat Options Oncol; 2016 Mar 15; 17(3):12. PubMed ID: 26931795
    [Abstract] [Full Text] [Related]

  • 9. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
    Henneman L, van Miltenburg MH, Michalak EM, Braumuller TM, Jaspers JE, Drenth AP, de Korte-Grimmerink R, Gogola E, Szuhai K, Schlicker A, Bin Ali R, Pritchard C, Huijbers IJ, Berns A, Rottenberg S, Jonkers J.
    Proc Natl Acad Sci U S A; 2015 Jul 07; 112(27):8409-14. PubMed ID: 26100884
    [Abstract] [Full Text] [Related]

  • 10. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V, Illuzzi G, Héberlé E, Dantzer F.
    Bull Cancer; 2015 Oct 07; 102(10):863-73. PubMed ID: 26384693
    [Abstract] [Full Text] [Related]

  • 11. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Piao J, Takai S, Kamiya T, Inukai T, Sugita K, Ohyashiki K, Delia D, Masutani M, Mizutani S, Takagi M.
    Cancer Lett; 2017 Feb 01; 386():131-140. PubMed ID: 27894958
    [Abstract] [Full Text] [Related]

  • 12. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
    McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC.
    Breast Cancer Res; 2014 Mar 14; 16(2):R25. PubMed ID: 24625110
    [Abstract] [Full Text] [Related]

  • 13. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
    Vaclová T, Woods NT, Megías D, Gomez-Lopez S, Setién F, García Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Monteiro ANA, Benítez J, Osorio A.
    Hum Mol Genet; 2016 Dec 15; 25(24):5287-5299. PubMed ID: 27742776
    [Abstract] [Full Text] [Related]

  • 14. Olaparib for the treatment of breast cancer.
    Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M.
    Expert Opin Investig Drugs; 2017 Jun 15; 26(6):751-759. PubMed ID: 28395540
    [Abstract] [Full Text] [Related]

  • 15. Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Józwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J.
    J Natl Cancer Inst; 2016 Nov 15; 108(11):. PubMed ID: 27381626
    [Abstract] [Full Text] [Related]

  • 16. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
    Wang W, Figg WD.
    Cancer Biol Ther; 2008 Jul 15; 7(7):1004-5. PubMed ID: 18720553
    [Abstract] [Full Text] [Related]

  • 17. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J, Mauritz M, Mitulovic G, Cupo M.
    J Cell Biochem; 2015 Dec 15; 116(12):2824-39. PubMed ID: 25981734
    [Abstract] [Full Text] [Related]

  • 18. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
    Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D.
    Cell Rep; 2016 Jan 26; 14(3):429-439. PubMed ID: 26774475
    [Abstract] [Full Text] [Related]

  • 19. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH.
    Cancer Lett; 2017 Feb 01; 386():47-56. PubMed ID: 27847302
    [Abstract] [Full Text] [Related]

  • 20. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
    Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR, Jonkers J.
    Cancer Cell; 2011 Dec 13; 20(6):797-809. PubMed ID: 22172724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.